Aphria sees huge growth opportunities—especially in Latin America and Europe. Last year, the company improved its position in Latin America and the Caribbean with its Latam Holdings acquisition. The deal gave Aphria access to Colombia, Argentina, and Jamaica. But the company faced allegations of significantly overpaying for the deal.

Germany’s a crucial market for growth in the medical cannabis space. Aphria’s one of three companies with cultivation licenses in Germany. It’s also the only licensed producer in Germany with permission to cultivate all three strains of medical cannabis that Germany has approved. The CC Pharma acquisition gave the company access to over 13,000 pharmacies in Germany and Europe. CC Pharma is a leading pharmaceutical distributor.

Last year, APHA also invested in Berlin’s Schöneberg Hospital. The move was part of its plan to operate pain treatment centers across Germany.

In April, Aphria introduced CannRelief to the German market. CannRelief is a hemp CBD–based nutraceutical and cosmetics product line. The company plans to offer a complete range of CBD products in Germany this year. Plus, its expansion plans should benefit from CCPharma’s extensive reach.

Aphria’s partnership with Althea also helps it tap into opportunities in Australia’s medical cannabis market. The company has a 25% stake in Althea.